DnB Asset Management AS Increases Stock Position in BioNTech SE (NASDAQ:BNTX)

DnB Asset Management AS lifted its holdings in BioNTech SE (NASDAQ:BNTX) by 23.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 37,999 shares of the company’s stock after purchasing an additional 7,219 shares during the period. DnB Asset Management AS’s holdings in BioNTech were worth $4,101,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of BNTX. Envestnet Asset Management Inc. lifted its position in shares of BioNTech by 4,861.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 972,535 shares of the company’s stock worth $1,531,000 after purchasing an additional 952,932 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of BioNTech in the 4th quarter worth approximately $49,796,000. BlackRock Inc. raised its stake in shares of BioNTech by 25.9% during the 1st quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock worth $274,768,000 after acquiring an additional 331,101 shares in the last quarter. Clearbridge Investments LLC bought a new position in shares of BioNTech during the 1st quarter worth approximately $31,326,000. Finally, Marshall Wace LLP raised its stake in shares of BioNTech by 164.3% during the 4th quarter. Marshall Wace LLP now owns 382,397 shares of the company’s stock worth $57,494,000 after acquiring an additional 237,709 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on BNTX shares. Morgan Stanley reduced their price objective on shares of BioNTech from $119.00 to $116.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 8th. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of BioNTech in a research note on Monday, August 28th. Finally, HSBC started coverage on shares of BioNTech in a research note on Friday, July 14th. They set a “buy” rating and a $124.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.69.

BioNTech Stock Down 0.7 %

NASDAQ:BNTX opened at $113.06 on Monday. The firm has a market capitalization of $27.25 billion, a P/E ratio of 6.34 and a beta of 0.17. BioNTech SE has a 1-year low of $95.50 and a 1-year high of $188.99. The company’s fifty day moving average price is $112.04 and its 200-day moving average price is $114.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.56 and a quick ratio of 10.32.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.04. The firm had revenue of $167.70 million for the quarter, compared to analyst estimates of $628.13 million. BioNTech had a net margin of 47.37% and a return on equity of 21.46%. The business’s quarterly revenue was down 94.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $7.31 earnings per share. As a group, equities research analysts anticipate that BioNTech SE will post 6.33 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.